SPOTLIGHT -
FDA Approves RSV Vaccine for Older Adults
The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.
Read More
FDA Approves Arexvy, the First RSV Vaccine for Older Adults
Older adults with comorbidities, including diabetes and chronic heart and lung disease, are at an increased risk of RSV hospitalization and death.
The Race to the First RSV Vaccine: How Close Are We, and Why Has It Been so Difficult?
Why has this season brought an unprecedented number of severe RSV infections, and why is vaccine development taking so long?
FDA Committee Recommends Approval for Live Microbiota C Difficile Medication
RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.
Real-World Study Shows RBX2660 Improves Recurrent C Difficile Infection
RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.
Strategies Are Developing to Boost HIV PrEP Initiation
Stigma, and a lack of communication and awareness all inhibit HIV PrEP uptake, but digital health and new forms of PrEP could boost users.
FDA Approves Long-Acting Monoclonal COVID-19 Prevention Treatment
In a recent clinical trial, Evusheld recipients at increased risk of severe COVID-19 infection saw a 77% reduced risk of developing COVID-19.
New Study Explores C Difficile Prevalence Outside of Healthcare
C difficile was found on 45% of shoe soles and 26.2% of private residences.
